Lanreotide Autogel in the Treatment of Idiopathic Refractory Diarrhea: Results of an Exploratory, Controlled, Before and After, Open-label, Multicenter, Prospective Clinical Trial

• Published in: Clinical therapeutics Vol. 38; no. 8; pp. 1902 - 1911.e2
• Main Authors: Bisschops, Raf, MD, PhD, De Ruyter, Vincent, MSc, Demolin, Gauthier, MD, Baert, Didier, MD, Moreels, Tom, MD, PhD, Pattyn, Piet, MD, PhD, Verhelst, Hans, MD, Lepoutre, Luc, MD, Arts, Joris, MD, Caenepeel, Philip, MD, PhD, Ooghe, Patrick, MD, Codden, Thierry, MD, Maisonobe, Pascal, MSc, Petrens, Elke, MSc, Tack, Jan, MD, PhD
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.08.2016; Elsevier Limited
• Subjects: Adult; Aged; chronic idiopathic refractory diarrhea; Clinical trials; Consent; Diarrhea; Diarrhea - drug therapy; Family medical history; Female; gastrointestinal motility; Gastrointestinal surgery; Growth hormones; Humans; Inflammatory bowel disease; Internal Medicine; Irritable bowel syndrome; lanreotide Autogel; Male; Medical Education; Middle Aged; Motility; open-label clinical trial; Peptides, Cyclic - administration & dosage; Polypeptides; Prospective Studies; Quality of Life; Somatostatin - administration & dosage; Somatostatin - analogs & derivatives; somatostatin analogue; Statistical analysis; Studies; Surveys and Questionnaires; Treatment Outcome; Tumors; Belgium; gastrointestinal motility; lanreotide Autogel; somatostatin analogue; chronic idiopathic refractory diarrhea; open-label clinical trial

Abstract Purpose Chronic idiopathic diarrhea is the passage of loose stools >3 times daily, or a stool weight >200 g/d, persisting for >4 weeks without clear clinical cause. Patients refractory to standard anti-diarrhetics have limited treatment options. Somatostatin analogues have the abil...